ARCHIVES

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

This article is from The Cancer Letter archive.

Vol. 24 No. 03 | January 23, 1998

Download PDF Visit The Full Archive

Related Articles

Advisors Say 10 Percent Payline “Not Tenable;” All NCI Programs Must Share Budget Cuts.

March 31, 2006

Three-Quarters of P01 $$ Goes To Translational Grants, NCI Finds

October 2, 1992

NTP Committee Accepts Industry Positions On Policy To Separate Figures for Benign, Malignant Lesions

November 7, 1980

Phase II Study: Proton Therapy Can Have Similar Success Rate, Smaller Level of Risk in Treatment of Hodgkin Lymphoma

July 25, 2014

MSKCC hopes to raise $1 billion in five-year campaign.

November 7, 2003

Adherez Issued U.S. Patent for Catenin Molecule Inhibition.

July 4, 2003